Price Chart

Profile

Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
URL https://www.editasmedicine.com
Investor Relations URL https://ir.editasmedicine.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 28, 2024
Last Earnings Release Nov. 03, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
URL https://www.editasmedicine.com
Investor Relations URL https://ir.editasmedicine.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 28, 2024
Last Earnings Release Nov. 03, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A